NASDAQ:GLTO Galecto Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Galecto, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.70 -0.03 (-1.73%) (As of 07/1/2022 08:00 PM ET) Add Compare Share Today's Range$1.70▼$1.7050-Day Range$1.22▼$2.3552-Week Range$1.17▼$5.15Volume15,000 shsAverage Volume94,313 shsMarket Capitalization$42.95 millionP/E RatioN/ADividend YieldN/APrice Target$7.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Galecto MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside311.8% Upside$7.00 Price TargetShort InterestHealthy0.28% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.39Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.64) to ($2.62) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.2.12 out of 5 starsMedical Sector345th out of 1,427 stocksPharmaceutical Preparations Industry162nd out of 680 stocks 3.5 Analyst's Opinion Consensus RatingGalecto has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.00, Galecto has a forecasted upside of 311.8% from its current price of $1.70.Amount of Analyst CoverageGalecto has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.28% of the float of Galecto has been sold short.Short Interest Ratio / Days to CoverGalecto has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Galecto has recently decreased by 17.77%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldGalecto does not currently pay a dividend.Dividend GrowthGalecto does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GLTO. Previous Next 4.1 News and Social Media Coverage News SentimentGalecto has a news sentiment score of 1.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Galecto this week, compared to 0 articles on an average week.Search Interest4 people have searched for GLTO on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows2 people have added Galecto to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Galecto insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.20% of the stock of Galecto is held by insiders.Percentage Held by InstitutionsOnly 39.81% of the stock of Galecto is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Galecto are expected to grow in the coming year, from ($2.64) to ($2.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Galecto is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Galecto is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGalecto has a P/B Ratio of 0.37. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive GLTO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Galecto and its competitors with MarketBeat's FREE daily newsletter. Email Address About Galecto (NASDAQ:GLTO) StockGalecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.Read More GLTO Stock News HeadlinesJune 22, 2022 | finance.yahoo.comInterstitial Lung Disease Clinical Trial Pipeline Insights | DelveInsight - Yahoo FinanceJune 16, 2022 | seekingalpha.comGalecto begins Phase 2 Trial of combo therapy to treat lung cancerJuly 4, 2022 | RJO Futures (Ad)Tailor an Options Trading Strategy to Fit Your NeedsThis guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile. Take your trading to the next level with the Options Strategy Guide. June 16, 2022 | globenewswire.comGalecto Announces First Patient Enrolled in Phase 2 Trial of GB1211 in Combination with Atezolizumab for First-Line Treatment of NSCLC - GlobeNewswireJune 16, 2022 | finance.yahoo.comGalecto Announces First Patient Enrolled in Phase 2 Trial of GB1211 in Combination with Atezolizumab for First-Line Treatment of NSCLCJune 4, 2022 | in.investing.comU.S. shares lower at close of trade; Dow Jones Industrial Average down 1.05% - Investing.com IndiaMay 31, 2022 | finance.yahoo.comSimply Better Brands Corp. Announces First Quarter 2022 Financial Results and Outlook for Continued Growth in 2022 - Yahoo FinanceMay 31, 2022 | benzinga.comGalecto to Participate at Jefferies Healthcare Conference - Benzinga - BenzingaJuly 4, 2022 | RJO Futures (Ad)Tailor an Options Trading Strategy to Fit Your NeedsThis guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile. Take your trading to the next level with the Options Strategy Guide. May 31, 2022 | globenewswire.comGalecto to Participate at Jefferies Healthcare Conference - GlobeNewswireMay 31, 2022 | finance.yahoo.comGalecto to Participate at Jefferies Healthcare ConferenceMay 26, 2022 | finance.yahoo.comGalecto to Present New Data on Oral Galectin-3 Inhibitor GB1211 at the 2022 ASCO Annual Meeting - Yahoo FinanceMay 26, 2022 | globenewswire.comGalecto to Present New Data on Oral Galectin-3 Inhibitor GB1211 at the 2022 ASCO Annual Meeting - GlobeNewswireMay 26, 2022 | finance.yahoo.comGalecto to Present New Data on Oral Galectin-3 Inhibitor GB1211 at the 2022 ASCO Annual MeetingApril 29, 2022 | finance.yahoo.comGalecto Reports First Quarter Operating and Financial ResultsApril 26, 2022 | finance.yahoo.comGalecto Completes Enrollment in Global Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of IPFMarch 29, 2022 | finance.yahoo.comGalecto Completes Enrollment in Phase 1b/2a GULLIVER-2 Trial of its Selective, Oral Galectin-3 Inhibitor GB1211 in Liver CirrhosisMarch 10, 2022 | nasdaq.comHere's Why You Should Retain Community Health (CYH) StockMarch 4, 2022 | nasdaq.comGalecto, Inc. (GLTO) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - NasdaqMarch 4, 2022 | finance.yahoo.comGalecto, Inc. (GLTO) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?March 2, 2022 | streetinsider.comOncoMyx Appoints Robert Williamson Chief Business and Chief Financial Officer - StreetInsider.comFebruary 17, 2022 | tmcnet.comGalecto Reports Financial Results for the Year EndedFebruary 17, 2022 | finance.yahoo.comGalecto Reports Financial Results for the Year Ended December 31, 2021February 7, 2022 | finance.yahoo.comGalecto to Participate at Upcoming Investor ConferencesJanuary 27, 2022 | finance.yahoo.comGalecto Publishes Results Showing Safety and Efficacy of the GB0139 Inhaled Galectin-3 Inhibitor in Hospitalized COVID-19 Patients on Standard of CareJanuary 5, 2022 | finance.yahoo.comGalecto Adds Experienced Biotech Executive Stephanie Oestreich as Chief Business OfficerDecember 20, 2021 | benzinga.comGalecto Says Has Enrolled 10 Of Anticipated 16 Patients In Phase 2a MYLOX-1 Trial; Reiterates Expected Timing Of Multiple Data Readouts In 2022See More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GLTO CUSIPN/A CIK1800315 Webgalecto.com Phone45-7070-5210FaxN/AEmployees28Year FoundedN/ACompany Calendar Last Earnings4/29/2022Today7/04/2022Next Earnings (Estimated)8/04/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$7.00 High Stock Price Forecast$7.00 Low Stock Price Forecast$7.00 Forecasted Upside/Downside+311.8%Consensus RatingBuy Rating Score (0-4)3 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($2.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-51,750,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-45.22% Return on Assets-43.08% Debt Debt-to-Equity RatioN/A Current Ratio13.45 Quick Ratio13.45 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.64 per share Price / Book0.37Miscellaneous Outstanding Shares25,262,000Free Float22,938,000Market Cap$42.95 million OptionableNot Optionable Beta0.19 Galecto Frequently Asked Questions Should I buy or sell Galecto stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Galecto in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Galecto stock. View analyst ratings for Galecto or view top-rated stocks. What is Galecto's stock price forecast for 2022? 1 analysts have issued 12-month target prices for Galecto's stock. Their GLTO stock forecasts range from $7.00 to $7.00. On average, they predict Galecto's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 311.8% from the stock's current price. View analysts' price targets for Galecto or view top-rated stocks among Wall Street analysts. How has Galecto's stock performed in 2022? Galecto's stock was trading at $3.03 on January 1st, 2022. Since then, GLTO shares have decreased by 43.9% and is now trading at $1.70. View the best growth stocks for 2022 here. When is Galecto's next earnings date? Galecto is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for Galecto. How were Galecto's earnings last quarter? Galecto, Inc. (NASDAQ:GLTO) released its earnings results on Friday, April, 29th. The company reported ($0.67) earnings per share (EPS) for the quarter. View Galecto's earnings history. Who are Galecto's key executives? Galecto's management team includes the following people: Dr. Hans T. Schambye M.D., Ph.D., Co-Founder, Pres, CEO & Director (Age 56, Pay $735.2k) (LinkedIn Profile)Mr. Jonathan P. Freve CPA, CPA, Chief Financial Officer (Age 44, Pay $602.4k) (LinkedIn Profile)Mr. Anders Pedersen, Chief Operating Officer (Age 62, Pay $540.39k)Mr. Ulf J. Nilsson, Co-FounderDr. Hakon Leffler, Co-FounderProf. Tariq Sethi M.D., B.Sc., M.A., Ph.D., FRCP, Co-Founder & Member of the Clinical Advisory Board - IPFMr. Garrett Winslow Esq., Sr. VP, Gen. Counsel & Corp. Sec. (Age 43) (LinkedIn Profile)Prof. Bertil Lindmark M.D., Ph.D., Chief Medical Officer (Age 67)Dr. Stephanie Oestreich Ph.D., Chief Bus. Officer (Age 48) Who are some of Galecto's key competitors? Some companies that are related to Galecto include XBiotech (XBIT), Vaccitech (VACC), Matinas BioPharma (MTNB), UroGen Pharma (URGN), Olema Pharmaceuticals (OLMA), Allakos (ALLK), Mereo BioPharma Group (MREO), Theratechnologies (THERF), Clene (CLNN), Sesen Bio (SESN), Concert Pharmaceuticals (CNCE), KemPharm (KMPH), Ovid Therapeutics (OVID), Nuvectis Pharma (NVCT) and Avadel Pharmaceuticals (AVDL). View all of GLTO's competitors. When did Galecto IPO? (GLTO) raised $86 million in an initial public offering (IPO) on Thursday, October 29th 2020. The company issued 5,700,000 shares at a price of $14.00-$16.00 per share. BofA Securities, SVB Leerink and Credit Suisse served as the underwriters for the IPO and Kempen & Co. was co-manager. What is Galecto's stock symbol? Galecto trades on the NASDAQ under the ticker symbol "GLTO." How do I buy shares of Galecto? Shares of GLTO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Galecto's stock price today? One share of GLTO stock can currently be purchased for approximately $1.70. How much money does Galecto make? Galecto (NASDAQ:GLTO) has a market capitalization of $42.95 million. The company earns $-51,750,000.00 in net income (profit) each year or ($2.19) on an earnings per share basis. How many employees does Galecto have? Galecto employs 28 workers across the globe. How can I contact Galecto? Galecto's mailing address is GALECTO BIOTECH AB OLE MAALOES VEJ3, COPENHAGEN G7, DK-2200. The official website for Galecto is galecto.com. The company can be reached via phone at 45-7070-5210. This page (NASDAQ:GLTO) was last updated on 7/4/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
